Global Sjogren's Syndrome Treatment Market Report and Forecast 2023-2031

Global Sjogren's Syndrome Treatment Market Report and Forecast 2023-2031

Global Sjogren's Syndrome Treatment Market Outlook

The global Sjogren's syndrome treatment market size was valued at USD 311.7 million in 2022 and is projected to grow at a CAGR of 4.0% during the forecast period of 2023-2031 to reach a value of USD 427.3 million by 2031. The market growth can be attributed to the increasing prevalence of Sjogren's syndrome and the rising awareness about the condition.

Global Sjogren's Syndrome Treatment Market: Introduction

Sjogren's syndrome treatment involves managing the symptoms and complications associated with the autoimmune disorder, primarily affecting the moisture-producing glands, such as the tear and salivary glands. The condition can also impact other organs and body systems, resulting in a variety of symptoms. Treatment options include medications, lifestyle modifications, and supportive therapies. The increasing prevalence of Sjogren's syndrome, along with rising awareness and the development of innovative treatment options, is driving the demand for Sjogren's syndrome treatment.

Advancements in diagnostics and therapeutics have played a significant role in the growth of the Sjogren's syndrome treatment market. Improved diagnostic techniques have enabled more accurate identification of the condition, leading to better management and treatment outcomes. Moreover, the development of targeted therapies and a better understanding of the underlying mechanisms of the condition contribute to the market's growth. Increased research and investment in Sjogren's syndrome treatment options have also fostered market expansion.

The Sjogren's syndrome treatment market is expected to continue to grow in the coming years, as awareness of the condition increases, and new treatment options and technologies are developed to meet the needs of patients with Sjogren's syndrome. However, there are still significant challenges in diagnosing the condition and providing appropriate treatment, particularly in low- and middle-income countries, where access to healthcare services may be limited.

Global Sjogren's Syndrome Treatment Market: Epidemiology

Sjogren's syndrome is a relatively common autoimmune disorder, affecting approximately 1 in 500 to 1 in 1,000 people worldwide. The condition is more prevalent in women, with a female-to-male ratio of approximately 9:1. Sjogren's syndrome can affect people of all ages, but it is most diagnosed in middle-aged adults. The increasing prevalence of the condition and the growing demand for effective treatment options are driving the growth of the Sjogren's syndrome treatment market.

Sjogren's Syndrome Treatment Market Segmentations

The market can be segmented based on drug class, indication type, therapeutics agents, route of administration, distribution channel, and region:

Market Breakup by Drug Class

  • Cholinergic Agonists
  • Off-Label Drugs
Market Breakup by indication Type
  • Primary Sjogren's Syndrome
  • Secondary Sjogren's Syndrome
Market Breakup by Therapeutics Agents
  • Targeted Drugs
  • Pain Relievers
  • Symptom Modulators
  • Vaccines
  • Others
Market Breakup by Route of Administration
  • Targeted Drugs
  • Pain Relievers
  • Symptom Modulators
  • Vaccines
  • Others
Market Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Market Breakup by Region
  • North America
  • United States of America
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others
Sjogren's Syndrome Treatment Market ScenarioAnalysis

The global Sjogren's syndrome treatment market has experienced significant growth over the past few years, driven by factors such as the increasing prevalence of Sjogren's syndrome, rising awareness about the condition, and the growing demand for innovative treatment options. North America is currently the largest market for Sjogren's syndrome treatment, accounting for a significant share of the global market. The region's large market share is driven by factors such as a high prevalence of Sjogren's syndrome, a well-established healthcare infrastructure, and strong investment in research and development.

Europe is also a significant market for Sjogren's syndrome treatment, with countries such as the UK, Germany, and France leading the way. The region's market growth is driven by factors such as a large population base, increasing awareness of Sjogren's syndrome, and government initiatives to address the condition.

Asia Pacific is another region that is experiencing significant growth in the Sjogren's syndrome treatment market. The region's market growth is driven by factors such as a large population base, increasing awareness of Sjogren's syndrome, and the growing adoption of innovative treatment options. In addition, government initiatives to address the condition are helping to drive the growth of the market in the region.

Key Players in the Global Sjogren's Syndrome Treatment Market

The report provides a detailed analysis of the key players involved in the Sjogren's syndrome treatment market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:
  • Denali Therapeutics
  • Clovis Oncology
  • Horizon Therapeutics plc
  • Sangamo Therapeutics
  • AbbVie Inc.
  • Advanz Pharma
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Hikma Pharmaceuticals plc
  • Johnson and Johnson
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Novartis AG

*Please Note:* The report will be completed in 7 business days after order confirmation


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Sjogren’s Syndrome Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Sjogren’s Syndrome Treatment Market
8.1 Global Sjogren’s Syndrome Treatment Market Overview
8.2 Global Sjogren’s Syndrome Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Sjogren’s Syndrome Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Sjogren’s Syndrome Treatment Market Forecast Value (2023-2031)
8.3 Global Sjogren’s Syndrome Treatment Market by Drug Class
8.3.1 Market Overview
8.3.1.1 Cholinergic Agonists
8.3.1.1.1 Salagen (Pilocarpine Hydrochloride)
8.3.1.1.2 Evoxac (Cevimeline Hydrochloride)
8.3.1.2 Off-Label Drugs
8.3.1.2.1 Tear and Saliva Substitutes
8.3.1.2.2 Cyclosporine Ophthalmic Emulsions – Restasis, Ikervis, Papilock Mini
8.3.1.2.3 Topical Ophthalmic Corticosteroids – Prednisolone, Fluorometholone, Loteprednol
8.3.1.2.4 Antimalarial Agents – Hydroxychloroquine
8.3.1.2.5 Other Systemic Immunosuppressive Therapies – Methotrexate, Azathioprine, Cyclophosphamide
8.3.1.2.6 Systemic Corticosteroids – Prednisolone, Methylprednisolone
8.3.1.2.7 Biologic Agents – Rituxan (Rituximab)
8.4 Global Sjogren’s Syndrome Treatment Market by Indication Type
8.4.1 Market Overview
8.4.1.1 Primary Sjogren's Syndrome
8.4.1.2 Secondary Sjogren's Syndrome
8.5 Global Sjogren’s Syndrome Treatment Market by Therapeutic Agents
8.5.1 Market Overview
8.5.1.1 Targeted Drugs
8.5.1.2 Pain Relievers
8.5.1.3 Symptom Modulators
8.5.1.4 Vaccines
8.5.1.5 Others
8.6 Global Sjogren’s Syndrome Treatment Market by Route of Administration
8.6.1 Market Overview
8.6.1.1 Oral
8.6.1.2 Intravenous
8.6.1.3 Subcutaneous
8.6.1.4 Others
8.7 Global Sjogren’s Syndrome Treatment Market by Distribution Channel
8.7.1 Market Overview
8.7.1.1 Retail Pharmacies
8.7.1.2 Hospital Based Pharmacies
8.7.1.3 Online Pharmacies
8.8 Global Sjogren’s Syndrome Treatment Market by Region
8.8.1 Market Overview
8.8.1.1 North America
8.8.1.2 Europe
8.8.1.3 Asia Pacific
8.8.1.4 Latin America
8.8.1.5 Middle East and Africa
9 North America Sjogren’s Syndrome Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Sjogren’s Syndrome Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Sjogren’s Syndrome Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Sjogren’s Syndrome Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Sjogren’s Syndrome Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Sjogren’s Syndrome Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives & Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Denali Therapeutics
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Clovis Oncology
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Horizon Therapeutics plc
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Sangamo Therapeutics
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 AbbVie Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Advanz Pharma
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Biogen Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Bristol-Myers Squibb Company
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Daiichi Sankyo Company, Limited
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Hikma Pharmaceuticals plc
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Johnson and Johnson
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 Sanofi S.A.
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
15.13 Sun Pharmaceutical Industries Limited
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
15.13.5 Certifications
15.14 Novartis AG
15.14.1 Company Overview
15.14.2 Product Portfolio
15.14.3 Demographic Reach and Achievements
15.14.4 Mergers and Acquisitions
15.14.5 Certifications
16 Global Sjogren’s Syndrome Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings